Alzheimer's Drug Targeting Soluble Amyloid Falls Short in a Large Clinical Trial
A paper reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.
Columbia University Irving Medical Center (CUIMC) led the multicenter study.
Researchers have proposed that Alzheimer’s disease is caused by the buildup of a sticky protein called beta-amyloid. According to this ‘amyloid hypothesis,’ the protein forms plaques in the brain that damage and eventually destroy brain cells. Solanezumab was designed to reduce the level of soluble amyloid molecules before they aggregate.
Click here to read more.
CARS 2018 Computer Assisted Radiology and Surgery
June 20-23, 2018; Berlin, Germany
2018 New England Neurosurgical Society Annual Meeting
June 28-30, 2018; Chatham, MA
15th International Congress on Neuromuscular Diseases
July 6-10, 2018; Vienna
International Summer School Transnasal Endoscopic Surgery: From Sinuses to Skull Base
July 9-13, 2018; Brescia, Italy
7th Annual World Course in Advanced Brain Tumor Surgery
July 12-15, 2018; London